FibroGen FY23 rev $147.8M (+5% YoY), net loss $284.2M; guides China roxadustat $300-340M

KYNTRA BIO, INC.

2023-FY EPS reported -$2.92 revenue$147,752,000

Full year 2023 total revenue $147.8M, up 5% YoY; net loss $284.2M ($2.92 per share), narrower than $293.7M loss in 2022.
Roxadustat net sales in China (FibroGen share) $100.9M in FY23, up 22% YoY; total China sales including JDE $284.1M (+36% YoY) driven by 41% volume growth.
Cash and equivalents $248.1M, with runway into 2026 after $120M annual cost reduction.
Pipeline: topline data from two pamrevlumab pancreatic cancer trials expected in 2Q 2024; Phase 1 FG-3246 data in mCRPC in 1Q 2024.
Guidance: FY 2024 FibroGen net product revenue $120-135M; total roxadustat China sales $300-340M; potential CIA approval in China mid-2024 with $10M milestone.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

KYNTRA BIO, INC. reported year ended December 31, 2023 results: revenue $147.8 million, net income Net loss for the year was $284.2 million, or $2.92 net loss per basic and diluted share, EPS $2.92 net loss per basic and diluted share.

Period: year ended December 31, 2023
Revenue: $147.8 million
Net income: Net loss for the year was $284.2 million, or $2.92 net loss per basic and diluted share
EPS: $2.92 net loss per basic and diluted share
Result: reported results

Exact text from the filing

2024 • FibroGen regains rights to roxadustat from AstraZeneca in the United States and other AstraZeneca territories, except China and South Korea • FY 2023 total net revenue of $147.8 million, an increase of 5% year over year • Robust roxadustat volume growth of 41% in China in FY 2023 compared to FY 2022 • Successful execution of cost reduction plan; $248.1 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

KYNTRA BIO, INC. reported quarter ended December 31, 2023 results: revenue $27.1 million, net income Net loss for the fourth quarter of 2023 was $56.2 million, or $0.57 net loss per basic and diluted share, EPS $0.57 net loss per basic and diluted share.

Period: quarter ended December 31, 2023
Revenue: $27.1 million
Net income: Net loss for the fourth quarter of 2023 was $56.2 million, or $0.57 net loss per basic and diluted share
EPS: $0.57 net loss per basic and diluted share
Result: reported results

Exact text from the filing

full year roxadustat net sales in China 1 by FibroGen and the JDE to range between $300 million to $340 million. Financial: • Total revenue for the fourth quarter of 2023 was $27.1 million, as compared to $34.4 million for the fourth quarter of 2022. Reduction primarily driven by the change in net product revenue assumptions under U.S. GAAP and drug product revenue

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

KYNTRA BIO, INC. reported 2024 results: revenue between $120 million to $135 million. Guidance reaffirmed.

Period: 2024
Revenue: between $120 million to $135 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

For 2024, we anticipate FibroGen’s full year net product revenue under U.S. GAAP to range between $120 million to $135 million, representing full year roxadustat net sales in China 1 by FibroGen and the JDE to range between $300 million to $340 million.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-020146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.